16th Feb 2016 09:16
LONDON (Alliance News) - Life sciences firm ValiRx PLC on Tuesday said a further set of subjects on its VAL201 cancer compound trial have completed their clinical dosing sequence with no significant adverse effects reported.
Due to this, the review committee on the trials has recommended the final dose escalation for the patients be approved.
ValiRx said the trial continues to progress on track and on budget and said it believes being able to dose patients at the final state with amounts which would be pre-clinically relevant is an important milestone for the drug.
ValiRx shares were down 0.7% to 15.40 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx